[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rectal-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rectal-cancer":697},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,236,0,25,[9,58,81,104,173,200,227,247,267,288,321,373,394,417,437,462,484,508,529,545,569,591,617,642,666],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100597545",false,"NCT07059884","Distance-Based Exercise to Preserve Function and Prevent Disability","DEFEND","Inclusion Criteria:\n\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must have histologically confirmed diagnosis of one of the following cancers: anus, bladder, breast, cervix, colon\u002Frectum, endometrium, esophagus, gallbladder, head\u002Fneck, kidney, liver, lung, ovary, pancreas, prostate, sarcoma, stomach\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Participants must be initiating outpatient cytotoxic chemotherapy for curative intent of at least 10 weeks duration (with or without concurrent radiation, immunotherapy, or other targeted therapy). Patients must be enrolled and baseline measures collected on or before administration of their second cycle of cytotoxic therapy. Patients receiving outpatient cytotoxic chemotherapy for curative intent in the neoadjuvant or adjuvant setting are eligible. Patients receiving definitive chemoradiation for the tumors listed above, are also eligible. Regimens of immunotherapy or monoclonal antibodies ONLY are not eligible\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Age 18-64 years\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have metastatic cancer\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of severe cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity. Examples would include unstable angina, recent myocardial infarction, oxygen-dependent pulmonary disease, and osteoarthritis requiring imminent joint replacement. Moderate arthritis that does not preclude physical activity is not a reason for ineligibility\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot be pregnant, because this study involves remotely delivered exercise, and cannot be breast-feeding as patients must be receiving cytotoxic chemotherapy, during which breast-feeding is contraindicated\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Patients cannot have documentation in the medical record of current alcohol, substance abuse, or dementia\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Engaged in full time gainful employment of at least 30 hours per week at the time of cancer diagnosis\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Currently no self-report of engagement in competitive sports (e.g. not training for running races, triathlons, etc.) AND no self-report of twice weekly progressive resistance exercise training for at least 3 consecutive months within the past year\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Self-reported ability to walk for 6 minutes (use of assistive devices will be allowed)\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Not participating in another weight loss, physical activity, or dietary intervention clinical trial\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Predicted 6MWT distance of 550 meters or less\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Concurrent enrollment in treatment or supportive care trials (other than those focused on weight loss or exercise) is allowed with the permission of the Alliance Executive Officer and both studies' study chairs\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): Eligibility is restricted to individuals who can comprehend and read English given that participation in the study will require the ability to read intervention materials and work with a coach through telehealth sessions\n* REGISTRATION ELIGIBILITY CRITERIA (STEP 1): The trial is unable to accommodate the needs of deaf or blind participants as the study relies on language and visualization of exercise through telehealth sessions\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Clinicians and research staff from enrolling sites who meet following criterion will be deemed eligible to participate as a clinical stakeholder:\n\n  \\* Providing clinical care for participating patients on this study\n* CLINICAL STAKEHOLDER ELIGIBILITY CRITERIA: Ability to speak and understand English\n\nExclusion Criteria:\n\n\\-","ALL","18 Years",{"count":19,"type":20},104,"ESTIMATED","INTERVENTIONAL",[23],"NA","This clinical trial studies whether an exercise program can be successfully delivered to patients receiving treatment for cancer through virtual sessions and allow patients to exercise in their own home. Treatments for cancer can cause side effects such as fatigue and loss of strength. These side effects can make it difficult to work, take care of family, and do other things the patient wants to do. Preliminary research shows that exercise can help prevent some of these side effects, but it can be more difficult to start an exercise program when a patient is receiving cancer treatment. The exercise program in this study is delivered through telehealth (TH) video calls. The TH sessions are delivered by trained staff that supervise resistance exercises. The trained staff also provide guidance to the patient on completing unsupervised aerobic sessions on their own. This may be a successful way to deliver an exercise program and make it easier for cancer patients to exercise in their own home during treatment.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Localized Malignant Solid Neoplasm","Anal Cancer","Bladder (Urothelial, Transitional Cell) Cancer","Breast Cancer","Cervical Cancer","Colon Cancer","Endometrial Cancer","Esophageal Cancer","Gall Bladder Cancer","Gastric Cancer","Kidney Cancer","Liver Cancer","Lung Cancer","Head and Neck Cancer","Ovarian Cancer","Pancreatic Cancer","Prostate Cancer","Rectal Cancer","Sarcoma","RECRUITING","2026-07-01",{"date":48,"type":49},"2026-07-02","ACTUAL",{"date":51,"type":49},"2026-02-11",{"date":53,"type":20},"2027-08-31",{"name":55,"class":56},"Alliance for Clinical Trials in Oncology","OTHER",18,{"id":59,"slug":4,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100487619","NCT05629442","ctDNA and Organ Preservation\u002FPathologic CR in Rectal Cancer","A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation or Pathologic Complete Response After Neoadjuvant Therapy for Rectal Cancer","Inclusion Criteria:\n\n* Participants with T3, T4, or node-positive non-metastatic rectal cancer.\n* Participants must have original tumor tissue (formalin-fixed, paraffin embedded specimens) available for analysis or be willing to undergo a baseline research biopsy.\n* Participants must be 18 years of age or older.\n* ECOG 0-2.\n* Participants must be eligible for at least 3 months of FOLFOX, FOLFIRINOX\u002FFOLFOXIRI, or CAPOX\n* Participants must be eligible for long course chemoradiation to 40-54 Gy.\n* Participants must be able to understand and willing to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Participants must not have any other organ cancer evident at the time of enrollment.\n* Participants may not have any other concurrent serious illness that makes participation on this study impractical or clinically inappropriate.\n* Participants must not be actively or planning to be pregnant or breastfeeding",{"count":65,"type":20},60,"OBSERVATIONAL","This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy.\n\nThis research study involves the collection of data and biospecimens (blood and tissue) to see if the presence of circulating tumor DNA (genetic material) ctDNA will help monitor rectal cancer more closely and potentially detect a recurrence before routine scans, performed per standard of care\n\nC2i Genomics, a biotechnology company, and the Spier Foundation are supporting this research study by providing funding for the study.",[43,69],"Non Metastatic Rectal Cancer",[43,69],"NOT_YET_RECRUITING","2026-06-29",{"date":46,"type":49},{"date":75,"type":20},"2026-10-01",{"date":77,"type":20},"2030-06",{"name":79,"class":56},"Massachusetts General Hospital",2,{"id":82,"slug":4,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100411885","NCT04643366","Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer","Phase 2 Study of Total Neoadjuvant mFOLFOX and Short-Course Radiotherapy in Resectable Rectal Cancer","Inclusion Criteria:\n\n* Pathologic diagnosis of adenocarcinoma of the rectum (diagnosis by tissue biopsy) within 90 days prior to registration. At least a portion of the tumor must be located below the peritoneal reflection or begin within 12 cm of the anal verge on flexible endoscopy\n* Clinically staged (AJCC 8th ed.) T3-4 N0 M0 or T any N1-2 M0 based upon the following minimum diagnostic workup:\n* Colonoscopy, unless patient presents with an obstructing lesion\n* Within 30 days before initiating MFOLFOX6 treatment:\n* History\u002Fphysical examination\n* Imaging to exclude distant metastases: either contrast-enhanced CT of the chest, abdomen, and pelvis; or whole-body PET-CT; or MRI\n* Pelvic MRI (preferred) or transrectal ultrasound (TRUS) for T staging Note: Patients may have initiated standard mFOLFOX6 treatment before study registration provided that they met the above criteria before initiating treatment and can feasibly continue to CRT according to the timeline described in Section\n* ECOG Performance Status ≤2\n* Age ≥ 18 years\n* Adequate bone marrow function defined as follows:\n* Absolute neutrophil count (ANC) ≥ 1,200 cells\u002Fmm3\n* Platelets ≥ 100,000 cells\u002Fmm3\n* Hemoglobin ≥ 8.0 g\u002FdL (Note: The use of transfusion or other intervention to achieve Hgb ≥8.0 g\u002FdL is acceptable.)\n* Adequate liver and renal function defined as follows:\n* AST and alkaline phosphatase \\\u003C 2.5 x upper limit of normal (ULN)\n* Bilirubin ≤ 2.5 ULN\n* Calculated creatinine clearance (CrCl) \\> 30 mL\u002Fmin using Cockcroft-Gault formula as calculated by the standard Cockcroft-Gault equation using age, actual weight, creatinine, and gender\n* Must be deemed a candidate for curative resection by the surgical oncologist who will be performing the operation\n* Women of childbearing potential (WCBP) must have a negative serum pregnancy test performed within 7 days prior to the start of chemotherapy.\n* WCBP and men must agree to use a medically accepted form of birth control during the treatment and for 3 months following completion of chemotherapy.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Prior RT that would result in unsafe overlap of RT fields with the planned study treatment, per the treating radiation oncologist\n* Clinically significant cardiac disease, including major cardiac dysfunction, that in the opinion of the treating medical oncologist would preclude them from receiving systemic therapy with 5-fluorouracil, leucovorin or oxaliplatin.\n* Serious (ie, ≥ grade 3) uncontrolled infection\n* Pulmonary or respiratory condition that, in the opinion of the treating medical oncologist would preclude them from receiving systemic therapy with 5-fluorouracil, leucovorin or oxaliplatin.\n* Major surgery within 28 days of study enrollment (other than diverting colostomy)\n* History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis) requiring significant intervention (eg, hospitalization, surgery, immunosuppressive medications) that would, in the opinion of the investigator, preclude study therapy\n* Prior known allergic reaction to 5-fluorouracil, leucovorin, or oxaliplatin\n* Known dipyrimidine dehydrogenase deficiency (DPD)\n* Any evidence of distant metastases (M1)\n* Pregnant or breast feeding\n* Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements",{"count":88,"type":20},64,[90],"PHASE2","This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.",[43],[94,95],"Resectable","Rectal",{"date":46,"type":49},{"date":98,"type":49},"2021-01-28",{"date":100,"type":20},"2032-01-31",{"name":102,"class":56},"Virginia Commonwealth University",4,{"id":105,"slug":4,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":110,"sex":16,"minAge":111,"maxAge":112,"enrollmentInfo":113,"targetDuration":115,"studyType":66,"phases":4,"briefSummary":116,"conditions":117,"keywords":154,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":172},"100210159","NCT02012699","Integrated Cancer Repository for Cancer Research","iCaRe2","Inclusion Criteria\n\n* Diagnosis\u002Fhistory of cancer\n* Risk for developing cancer or suspicious clinical findings\n* No history of cancer (normal control registry)\n* Able to provide informed consent\n* 19 years of age or older\n* English or Spanish speaking individuals\n\nExclusion Criteria\n\n* Unable to provide informed consent because of cognitive impairment\n* Non-English or non-Spanish speaking individuals",true,"19 Years","110 Years",{"count":114,"type":20},999999,"80 Years","The iCaRe2 is a multi-institutional resource created and maintained by the Fred \\& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.",[41,118,38,33,119,31,43,120,27,121,122,123,35,37,124,125,126,127,128,36,129,42,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,29,146,147,44,148,149,40,32,150,151,152,153],"Thyroid Cancer","Thymus Cancer","Gastrointestinal Stromal Tumors","Bile Duct Cancer","Duodenal Cancer","Gallbladder Cancer","Small Intestine Cancer","Peritoneal Surface Malignancies","Familial Adenomatous Polyposis","Lynch Syndrome","Bladder Cancer","Penile Cancer","Testicular Cancer","Ureter Cancer","Urethral Cancer","Hypopharyngeal Cancer","Laryngeal Cancer","Lip Cancer","Oral Cavity Cancer","Nasopharyngeal Cancer","Oropharyngeal Cancer","Paranasal Sinus Cancer","Nasal Cavity Cancer","Salivary Gland Cancer","Skin Cancer","Central Nervous System Tumor","Central Nervous System Cancer","Mesothelioma","Leukemia","Melanoma","Unknown Primary Tumor","Multiple Myeloma","Vaginal Cancer","Neuroendocrine Tumors","Plasma Cell Dyscrasia","Healthy Control",[41,118,155,156,157,158,159,160,161,162,29,163,152,153],"Esophageal cancer","Thymus cancer","Pancreatic tumor","Esophageal tumor","Thymus tumor","Thyroid Tumor","Thyroid Nodule","Lung Tumor","Neuroendocrine tumor","2026-06-25",{"date":72,"type":49},{"date":167,"type":49},"2013-11-01",{"date":169,"type":20},"2099-12",{"name":171,"class":56},"University of Nebraska",42,{"id":174,"slug":4,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":4,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":21,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":199},"100560442","NCT06577194","Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer","A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n* Males and females aged between 18 and 70 years;\n* ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1;\n* Tumor tissue samples obtained and histologically confirmed as rectal adenocarcinoma;\n* Adequate hematological, liver, and kidney functions: neutrophil count ≥ 1.5×10\\^9\u002FL; platelet count ≥ 75×10\\^9\u002FL; serum total bilirubin ≤ 1.5× upper limit of normal (UNL); aspartate aminotransferase ≤ 2.5× UNL; alanine aminotransferase ≤ 2.5× UNL; serum creatinine ≤ 1.5× UNL.\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV);\n* Recurrent rectal cancer;\n* Concurrent active bleeding, perforation, or other complex situations that cannot be addressed with emergency colostomy surgery alone;\n* Previous systemic anti-cancer treatment for colorectal cancer;\n* Coexistence of other non-colorectal cancer malignancies;\n* Patients with any active autoimmune diseases, or a history of needing steroids or immunosuppressive drugs;\n* Patients with interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, and acute pneumonia);\n* Previous treatment-induced any grade 2 or above toxicity reaction (according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5 classification) that has not subsided (excluding anemia, hair loss, and skin pigmentation);\n* Previous treatment with anti-programmed death receptor-1 (PD-1) or its ligand (PD-L1) antibodies, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies;\n* Pregnant or breastfeeding women;\n* Known or tested positive for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS);\n* Known or suspected allergy history to any drugs used in the trial.","70 Years",{"count":181,"type":20},35,[90],"A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer",[43,185],"Advanced Solid Tumor",[187,188,189],"Immunotherapy","Short-course radiotherapy","IL-2","2026-06-22",{"date":192,"type":49},"2026-06-24",{"date":194,"type":49},"2024-10-05",{"date":196,"type":20},"2028-10-31",{"name":198,"class":56},"The First Affiliated Hospital with Nanjing Medical University",1,{"id":201,"slug":4,"hasResults":11,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100643988","NCT07669298","Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer","Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer: Multicentre Randomised Controlled Trial","T-REX","Inclusion Criteria:\n\n1. Pathologically confirmed rectal cancer located extraperitoneally.\n2. Complete tumour resection (R0) by means of ESD or IMD (endoscopic or TAMIS).\n3. Pathological report indicative of:\n\n   \\- pT1 with at least 1 of the following features: poor histological differentiation (grade 3), vascular invasion, lymphatic invasion, high tumour budding (grade 2-3), sm2 or sm3 invasion.\n4. Endoscopic images or video of the tumour before local excision.\n5. Maximum cancer diameter ≤ 30 mm based on the pathological assessment.\n6. cN0 stage based on pelvic MRI; lymph nodes smaller than 10 mm will be considered as benign, independent of morphologic features. Staging must be performed within 6 weeks before randomisation.\n\n   \\- If enlarged lymph nodes are present on MRI performed after ESD\u002FIMD (raising the possibility of reactive inflammatory change), fine needle aspiration (FNA) will be undertaken, and patients with negative FNA cytology will remain eligible.\n7. Adequate distant staging (thoracic and abdominal CT) without signs of distant metastasis (cM0).\n8. Have undergone a high-quality full colonoscopy:\n\n   * Boston Bowel Preparation Scale score equal or greater than 2 in all colonic segments.\n   * Documented caecal intubation.\n   * All polyps ≥20 mm in diameter other than the index lesion must be completely removed and assessed pathologically.\n9. Expected survival time of more than 12 months from randomisation.\n10. At least 18 years old at the time of informed consent.\n11. Eastern Cooperative Oncology Group performance status (ECOG PS) 0, 1 or 2.\n12. Adequate hematologic function, based upon meeting the following laboratory criteria within 7 days before randomisation:\n\n    * Absolute neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL.\n    * Haemoglobin (Hb) ≥ 8.0 g\u002FdL (red blood cell transfusions are allowed to reach the target level).\n    * Platelet count ≥ 75 × 10\\^9\u002FL.\n13. Adequate liver function, based upon meeting the following criteria within 7 days before randomisation:\n\n    * Serum albumin ≥ 3.0 g\u002FdL.\n    * Total bilirubin (in serum) ≤ 2.0 mg\u002FdL.\n    * Aspartate aminotransferase (AST) ≤ 3 × the upper limit of normal (ULN).\n    * Alanine aminotransferase (ALT) ≤ 3× ULN.\n    * Alkaline phosphatase (ALP) ≤ 3 × ULN.\n14. Adequate coagulation defined by International Normalized Ratio (INR) ≤ 2.0 within 7 days before randomisation.\n15. Adequate renal function, based upon meeting the following laboratory criteria within 7 days before randomisation:\n\n    * Serum creatinine clearance ≥ 50 mL\u002Fmin calculated using the Cockcroft-Gault formula.\n    * Absence of significant proteinuria. If the subject is found to have dipstick test indicative of proteinuria equal or larger than 2+, or lab urinalysis for protein is greater than or equal to 1 g\u002FL, the subject must demonstrate urine protein \\\u003C 1 g\u002F24 h to be eligible.\n16. Recovery from prior treatment-related toxicities to \\\u003C Grade 2 severity per CTCAE v6.0, unless the adverse events are clinically nonsignificant and\u002For stable on supportive therapy.\n17. Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study treatment. This does not apply to postmenopausal women (amenorrhoeic for at least 12 consecutive months), women aged above 55, or surgically sterilized patients (men and women).\n18. Female participants of childbearing potential must not be lactating or pregnant, with a negative beta-human chorionic gonadotropin (beta-hCG) test (blood or urine) at screening and before the first dose of the study treatment.\n\n    Females of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e., females who have had any evidence of menses in the past 12 months, except for those who had prior hysterectomy). However, women who have been amenorrhoeic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antioestrogens, ovarian suppression, low body weight, or other reasons.\n19. Written informed consent to participate in the study provided before randomisation.\n20. Capability of understanding and complying with the protocol requirements.\n21. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.\n22. Eligibility for thoracic, abdominal and pelvic CT and MRI.\n\nExclusion Criteria:\n\n1. Suspicion of distant metastases on computed tomography of the abdomen or thorax or lymph node involvement (lymph nodes \\>9mm in short axis); In case of isolated enlarged nodes biopsy will be required before exclusion.\n2. Mesorectal tumour involvement on pelvic MRI.\n3. Synchronous colorectal cancer in screening colonoscopy.\n4. Known genetic cancer syndrome, including, but not limited to adenomatous or serrated polyposis syndrome; Lynch or Lynch-like syndrome.\n5. Known inflammatory bowel disease.\n6. Previously identified allergy or hypersensitivity to 5-FU or capecitabine.\n7. Known or suspected dihydropyridine dehydrogenase (DPD) deficiency.\n8. Prior receipt of pelvic radiation.\n9. Other contraindications to pelvic irradiation.\n10. Serious illness other than cancer that would preclude safe participation in the study\n11. Uncontrolled and significant condition, including, but not limited to, the following conditions:\n\n    * Heart failure NYHA II or above.\n    * Major cardiac arrhythmia.\n    * Myocardial infarction within 6 months before randomisation.\n    * Unstable angina pectoris.\n    * Stroke (including transient ischemic attack, TIA) within 6 months before randomisation.\n    * Thromboembolism within 3 months before randomisation.\n    * History of hypertensive crisis.\n12. Gastrointestinal disorders associated with a high risk of perforation or fistula formation.\n13. Gastrointestinal bleeding event within 28 days of randomisation.\n14. Major surgery performed within 4 weeks prior to randomisation or scheduled for surgery during the study period. Complete healing from major surgery must have occurred 1 month before randomisation. Complete healing from minor surgery must have occurred at least 7 days before randomisation.\n15. Serious non-healing wound or bone fracture.\n16. Malabsorption syndrome.\n17. Pregnancy or lactation.\n18. Mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H).",{"count":208,"type":20},480,[23],"The goal of this clinical trial is to learn if close follow-up alone (active surveillance) works as well as radiation combined with chemotherapy (chemoradiotherapy) after removing early rectal cancer in adults. The main questions it aims to answer are:\n\n1. Does active surveillance cause fewer serious adverse events than chemoradiotherapy within 3 years? Serious adverse events include a permanent or temporary ostomy (a surgical opening in the belly to pass stool), major bowel problems, or severe treatment-related complications.\n2. Is active surveillance as safe as chemoradiotherapy in preventing cancer from coming back or spreading within 3 years?\n\nResearchers will compare active surveillance to chemoradiotherapy to see if surveillance causes fewer serious adverse events while keeping cancer outcomes comparable.\n\nTo join this study, participants must be adults who had an early-stage rectal cancer (T1) removed by an endoscopic procedure, and whose removed tumor showed certain features that raise the risk of cancer cells remaining nearby.\n\nParticipants will be randomly placed in one of two groups:\n\n1. Active surveillance group: Participants will have regular checkups, blood tests, flexible camera exams of the bowel (rectoscopy), scans of the pelvis and abdomen, and colonoscopy on a set schedule for 5 years. If cancer comes back, doctors will propose further treatment options.\n2. Chemoradiotherapy group: Participants will receive radiation to the pelvis along with a chemotherapy pill (capecitabine) or an intravenous (IV) chemotherapy drug (5-FU) for about 5 weeks. After treatment, they will have regular checkups and scans for 5 years.",[43],[213,214,215,216,217],"early rectal cancer","local excision","active surveillance","adjuvant chemoradiotherapy","organ preservation","2026-06-20",{"date":164,"type":49},{"date":221,"type":49},"2026-06-14",{"date":223,"type":20},"2037-06",{"name":225,"class":56},"Medical University of Gdansk",3,{"id":228,"slug":4,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":230,"acronym":231,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":234,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":199},"100498609","NCT05772481","Interest of PET-MRI in the Evaluation of the Response After Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma","TEPIREC","Inclusion Criteria:\n\n* World Health Organization (WHO)\u002FEastern Cooperative Oncology Group (ECOG) 0 to 2\n* Histologically proven rectal cancer\n* clinical tumor classification (cT) : cT3 - cT4 or all T \u002F N+ \u002F M0\n* Tumor resectable or considered resectable after chemoradiotherapy\n* Decision chemotherapy followed by neoadjuvant chemoradiotherapy decided at the organ Multidisciplinary Meeting\n* Absence of distant metastases\n* Adequate contraception for women of childbearing potential\n* Free, signed and informed consent\n* For women of childbearing potential : negative pregnancy test\n\nExclusion Criteria:\n\n* Subject with Uncontrolled diabetes\n* Contraindication to surgery\n* Contraindication to MRI\n* Contraindication to PET scan\n* Contraindication to chemotherapy\n* History of pelvic radiotherapy\n* History of major co-morbidity that may prevent treatment and no active infection (HIV or chronic hepatitis B or C)\n* Colloid (mucinous) adenocarcinoma\n* Presence of distant metastases\n* Contraindication to 5-FluoroUracil (FU), oxaliplatin or irinotecan\n* History of known Gilbert's disease\n* Patient with known UGT1A1 genotype\n* Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency\n* Medical history of chronic diarrhea or inflammatory disease of the colon or rectum\n* Medical history of angina or myocardial infarction.\n* Active progressive infection or any other serious medical condition that could compromise the administration of the treatment\n* Other concurrent cancer, or medical history of cancer other than treated in situ cervical carcinoma or basal cell carcinoma or squamous cell carcinoma\n* Patient enrolled in another clinical trial testing an investigational agent\n* Pregnant or breastfeeding woman\n* Persons deprived of their freedom or under guardianship or incapable of giving consent\n* Any psychological, familial, sociological or geographic condition that may interfere with the study protocol or follow-up schedule","75 Years",{"count":235,"type":20},50,"With 50 patients included, this trial would be the largest pilot study evaluating the value of MRI PET in locally advanced rectal cancer. On the other hand, it would be the only pilot study performing several MRI PET during neoadjuvant treatment. Presumably, the response assessed at the 2nd MRI PET (before cycle 4 or induction chemotherapy) would be predictive of the overall response at the end of neoadjuvant treatment. Then, it would be possible to predict precociously the tumor response.",[43],"2026-06-16",{"date":240,"type":49},"2026-06-17",{"date":242,"type":49},"2023-05-19",{"date":244,"type":20},"2030-07-25",{"name":246,"class":56},"Centre Paul Strauss",{"id":248,"slug":4,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":256,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":265,"locationsCount":199},"100609071","NCT07209787","SIS-Reinforced vs. Conventional Anastomosis for Mid-to-Low Rectal Cancer: A Multicenter RCT on Anastomotic Leak","A Prospective, Multicenter, Randomized Controlled Study Comparing Effect of Conventional Versus SIS-Reinforced Rectum Anastomosis On Anastomotic Leak Following Radical Resection of Mid-to-Low Rectal Cancer（SISReal）","Inclusion Criteria--\n\n1. Age ≤ 85 years old, regardless of gender.\n2. Patients with mid - low rectal cancer, where the lower edge of the cancer focus is ≤ 10 cm from the anus and who can undergo rectal anastomosis with a circular stapler (including mid - low and some ultra - low rectal anastomoses). This includes patients after neoadjuvant therapy, patients with insufficient function of important organs such as the heart, liver, and kidneys who can tolerate surgery, and patients after intestinal obstruction stent placement or chemotherapy after intestinal obstruction stent placement.\n3. For patients who, after being fully informed by doctors, still clearly refuse neoadjuvant therapy (for advanced rectal cancer) and\u002For immunotherapy (for MSI - H\u002FdMMR rectal cancer) and request direct surgery, they are generally not included in this study. If a patient insists on enrolling, the operating surgeon must have a second conversation with the patient and\u002For their family members, and sign in the medical record to confirm the following: The patient is aware of the existence of the neoadjuvant therapy\u002Fimmunotherapy pathway but refuses the relevant treatment and insists on direct surgery. Only in this case can the patient be allowed to enroll.\n4. Patients who received conversion therapy due to distant organ (such as liver, lung) metastasis before surgery and then underwent surgery with primary anastomosis can be included in this study. If organ metastasis is accidentally found during surgery, or if the small intestine or bladder in the pelvic floor is invaded, but the surgeon believes it does not affect rectal anastomosis, the patient does not need to withdraw from the study.\n5. The patient or their authorized representative voluntarily signs the informed consent form and can cooperate to complete the follow - up during the trial.\n\nExclusion Criteria--\n\n1. Patients who, through examination and pre - operative consultation, cannot tolerate routine surgery.\n2. Patients who are currently participating in other clinical studies.\n3. Since the test device (SIS reinforcement patch) is derived from porcine - sourced materials, out of respect for specific religious beliefs (such as Islam), we do not recommend that subjects whose beliefs prohibit contact with porcine - sourced products participate in this study. We will fully communicate this situation with all potential subjects, and the subjects will make their own decisions based on their personal beliefs and cultural backgrounds.\n4. Patients who do not meet the NCCN and the National Health Commission of China's treatment standards for rectal cancer will not be included in this study. For example, patients who should receive neoadjuvant therapy before surgery should preferentially choose neoadjuvant therapy, and MSI - H\u002FdMMR patients are required to undergo immunotherapy first.\n5. Due to the possible difficulty in matching the number of patients\u002Fomissions with regular patients, patients who require lateral lymph node dissection and those who receive Ta - TME will not be included in this study.\n6. Patients who, due to language or intellectual disabilities, cannot understand the content of the trial protocol, cannot complete the follow - up, or for whom the researcher deems there are other situations that are not suitable for enrollment (such as uncontrolled severe underlying diseases, mental illness, etc.).","85 Years",{"count":255,"type":20},966,[257],"PHASE4","The goal of this clinical trial is to learn whether using a reinforcing material called SIS (small intestinal submucosa) during bowel connection after rectal cancer surgery can help prevent anastomotic leakage-a serious complication where the connection between two parts of the intestine fails to heal properly. This study will focus on patients with mid-to-low rectal cancer who are scheduled for surgery.\n\nThe main questions the study aims to answer are:\n\nDoes using an SIS-reinforced connection reduce the rate of anastomotic leakage within 30 days after surgery compared to standard connection methods?\n\nDoes it also reduce the need for a temporary stoma (an opening in the abdomen for waste removal)?\n\nResearchers will compare two groups:\n\nIntervention group: Patients who receive the SIS-reinforced connection during surgery.\n\nControl group: Patients who receive the standard connection without reinforcement.\n\nParticipants in this study will:\n\nBe randomly assigned to either the intervention or control group.\n\nUndergo standard laparoscopic or robot-assisted rectal cancer surgery.\n\nBe followed up at 30 days, 90 days, and 12 months after surgery to check for complications, stoma status, and quality of life.\n\nThis study is being conducted across multiple hospitals in China to ensure the results are reliable and widely applicable.",[43],"2026-06-15",{"date":240,"type":49},{"date":263,"type":49},"2025-10-21",{"date":53,"type":20},{"name":266,"class":56},"Beijing Chao Yang Hospital",{"id":268,"slug":4,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":287},"100511728","NCT05943210","The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer","The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer.","ROBIN","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of adenocarcinoma of the rectum\n* Age ≥ 18 years\n* ECOG performance status 0-1\n* cT2-T3N0 or cT1-3N1 or cT4 or cN2\n* Rectal cancer amenable to total mesorectal excision\n* No evidence of distant metastases\n* No prior pelvic radiation therapy\n* No prior chemotherapy or surgery for rectal cancer\n* Total neoadjuvant therapy (short course radiotherapy followed by consolidative chemotherapy) is allowed\n* No infections requiring systemic antibiotic treatment\n* Hgb \\>8.0 gm\u002FdL, PLT \\> 150,000\u002Fmm3, total bilirubin ≤ 1.5x upper limit of normal, AST ≤ upper limit of normal, ALT ≤ 3x upper limit of normal\n* Patients must read, agree to, and sign a statement of informed consent prior to participation in this study. Patients who do not read or understand English or eligible but must have the consent form read to them in its entirety by an official translator. Informed consent for non-literate or non-English speaking patients may not be obtained by using a relative or a member of the patient's clinical team as a translator.\n* Female participants or reproductive potential, defined as not surgically sterilized and between menarche and 1 year post menopause, must have a negative serum pregnancy test within 4 weeks prior to initiation of study treatment.\n* Women with childbearing potential who are negative for pregnancy (urine or blood) and who agree to use effective contraceptive methods. A woman of childbearing potential is defined by one who is biologically capable of becoming pregnant. Reliable contraception should be used from trial screening and must be continued throughout the study.\n\nExclusion Criteria:\n\n* Recurrent rectal cancer\n* Primary unresectable rectal cancer is defined as a primary rectal tumor which, on the basis of either physical exam or pelvic MRI, is deemed to be adherent or fixed to adjacent pelvic structures (en bloc resection will not be achieved with negative margins).\n* Patients who have received prior pelvic radiotherapy\n* Patients with prior allogenic stem cell or solid organ transplantation.\n* Patients receiving treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor-α agents) administered at \\>10 mg\u002Fday prednisone or equivalent within 2 weeks prior to initiation of study treatment.\n* Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment would make them inappropriate candidates for entry into this study\n* Patients receiving other anticancer or experimental therapy. No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF\u002FFlk-1 monoclonal antibody, or other experimental drugs) of any kind are permitted while the patient is receiving study treatment.\n* Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to four weeks after the study.","90 Years",{"count":7,"type":20},[23],"This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.",[43],"2026-06-11",{"date":260,"type":49},{"date":282,"type":49},"2023-05-22",{"date":284,"type":20},"2028-05-31",{"name":286,"class":56},"Weill Medical College of Cornell University",5,{"id":289,"slug":4,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":295,"targetDuration":4,"studyType":21,"phases":296,"briefSummary":297,"conditions":298,"keywords":301,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":320},"100593833","NCT07011576","A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","A Phase II Study Investigating Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)","FRUITFUL","Key Inclusion Criteria:\n\n* Confirmed mCRC ; histologically documented adenocarcinoma of the colon or rectum with at least one measurable lesion according to RECIST v1.\n* Genetic aberrations are allowed, except for microsatellite instability high (MSI-H) and BRAF V600\n* Participants must have received first-line therapy for mCRC that included oxaliplatin, a fluoropyrimidine, and a BEV-based agent. FOLFOXIRI, BEV, and SOX\u002FBEV regimes are not permitted. A minimum of 2 cycles of first line of therapy must have been completed.\n* At least 18 years-of-age at the time of signature of the Informed Consent Form (ICF)\n* Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2\n\nKey Exclusion Criteria:\n\n* Current treatment with other anticancer treatments within 21 days of the first dose of study treatment\n* Major surgery within 4 weeks of the first planned dose of study treatment\n* More than one prior systemic treatment for mCRC or any prior systemic treatment including FOLFIRI or irinotecan-based therapy.\n* Participants who received oxaliplatin and fluoropyrimidine in the first line neoadjuvant or adjuvant setting (prior to Metastatic diagnosis) and progressed within 6 months are not eligible due to lack of BEV exposure.\n* Uncontrolled, symptomatic brain metastases\n* Uncontrolled, symptomatic gastrointestinal disease\n* Participants with uncontrolled hypertension\n* Women who are pregnant, nursing, or plan to become pregnant while in the study and for at least 6 months after the last administration of study chemotherapy\n* Men who plan to father a child while in the study and for at least 6 months after the last administration of study chemotherapy\n* Documented major electrocardiogram (ECG) abnormalities which are clinically significant.\n* Symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment\n* Presence of other active invasive cancers other than the one treated in this study within 5 years prior to screening",{"count":65,"type":20},[90],"This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of this study are to:\n\n* Evaluate the efficacy of the combination of fruquintinib + FOLFIRI in the 2nd-line mCRC setting\n* Evaluate the safety of the combination of fruquintinib + FOLFIRI",[31,43,299,300],"Colorectal Cancer","Colorectal Cancer (CRC)",[302,31,303,304,305,306,307,308,309,310],"Colorectal cancer","Rectal cancer","Metastatic colorectal cancer","mCRC","VEGFR inhibitor","Fruquintinib","FOLFIRI","Second line","2L mCRC","2026-06-10",{"date":313,"type":49},"2026-06-12",{"date":315,"type":49},"2025-09-29",{"date":317,"type":20},"2027-06",{"name":319,"class":56},"SCRI Development Innovations, LLC",14,{"id":322,"slug":4,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":21,"phases":330,"briefSummary":332,"conditions":333,"keywords":348,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":372},"100520064","NCT06051695","A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","A Seamless Phase 1\u002F2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod™ CAR T Products, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","EVEREST-2","Inclusion Criteria:\n\nKey Inclusion Criteria:\n\n1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A\\*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy\n2. Histologically confirmed recurrent unresectable, locally advanced, or metastatic CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. Measurable disease is required with lesions of ≥1.0 cm by CT.\n3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol\n4. Has adequate organ function as described in the protocol\n5. ECOG performance status of 0 to 1\n6. Life expectancy of ≥3 months\n7. Willing to comply with study schedule of assessments including long term safety follow up\n\nKey Exclusion Criteria:\n\n1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative\n2. Prior allogeneic stem cell transplant\n3. Prior solid organ transplant\n4. MESO with pleural involvement extending into the peritoneum\n5. Cancer therapy within 3 weeks or 3 half lives of infusion\n6. Radiotherapy within 28 days of infusion\n7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months\n8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated\n9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged steroids or other immune suppressive agents within 1 year\n10. Requires supplemental home oxygen\n11. Females of childbearing potential who are pregnant or breastfeeding\n12. Subjects, both male and female, of childbearing potential who are not willing to practice birth control from the time of consent through 6 months post infusion",{"count":329,"type":20},474,[331,90],"PHASE1","The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\\*02 expression.\n\nThe main questions this study aims to answer are:\n\nPhase 1: What is the recommended dose that is safe for patients\n\nPhase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells\n\nParticipants will be required to perform study procedures and assessments, and will also receive the following study treatments:\n\nEnrollment and Apheresis in BASECAMP-1 (NCT04981119)\n\nPreconditioning Lymphodepletion (PCLD) Regimen\n\nTmod CAR T cells at the assigned dose",[334,299,335,336,337,338,339,340,341,342,31,43,343,40,344,145,345,346,38,347],"Solid Tumor, Adult","NSCLC","Non Small Cell Lung Cancer","NSCLC, Recurrent","Non-Small Cell Squamous Lung Cancer","Pancreas Cancer","Pancreatic Neoplasm","Colorectal Adenocarcinoma","CRC","Cancer","Ovarian Neoplasms","Mesothelioma, Malignant","Ovary Cancer","MESOM",[349,350,351,352,353,354,355,356,357,358,359,360,343,361,342,299,38,335,362,347,40,145,363],"CAR T Cell","Solid Tumors","Autologous","T Cell","Mesothelin","MSLN","HLA-A2","Solid Tumors expressing MSLN","Pancreatic","Cell Therapy","Gene Therapy","blocker","PANC","OVCA","Logic-gate",{"date":313,"type":49},{"date":366,"type":49},"2024-04-03",{"date":368,"type":20},"2029-06",{"name":370,"class":371},"A2 Biotherapeutics Inc.","INDUSTRY",12,{"id":374,"slug":4,"hasResults":11,"nctId":375,"briefTitle":376,"officialTitle":377,"acronym":378,"eligibilityCriteria":379,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":179,"enrollmentInfo":380,"targetDuration":4,"studyType":21,"phases":382,"briefSummary":383,"conditions":384,"keywords":386,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":199},"100641725","NCT07646639","Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC","Different-Dose Short-Course Radiotherapy Plus CAPOX, Anti-PD-1 Antibody and Interleukin-2 for Locally Advanced Rectal Cancer: A Single-Centre, Prospective, Randomised Phase II Trial","PRIDE-02","Inclusion Criteria:\n\n1. Male and female patients aged 18 to 70 years.\n2. Histologically confirmed rectal adenocarcinoma with the distal margin of the tumor located within 12 cm of the anal verge.\n3. MRI-based clinical stage T3-T4 or any T with lymph node-positive (N+) disease.\n4. Adequate hematologic, hepatic, and renal function defined as: absolute neutrophil count \\>=1.5 x 10\\^9\u002FL; platelet count \\>=75 x 10\\^9\u002FL; serum total bilirubin \\\u003C=1.5 x upper normal limit (UNL); aspartate aminotransferase \\\u003C=2.5 x UNL; alanine aminotransferase \\\u003C=2.5 x UNL; serum creatinine \\\u003C=1.5 x UNL.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n\nExclusion Criteria:\n\n1. Metastatic disease (Stage IV).\n2. Recurrent rectal cancer.\n3. Concurrent active bleeding, perforation, or other complicated conditions requiring emergency surgery.\n4. Prior systemic anticancer therapy for rectal cancer.\n5. Presence of another non-colorectal neoplastic disease at the same time.\n6. Patients with any active autoimmune disease or a history of autoimmune disease requiring steroids or immunomodulatory therapy.\n7. Patients with interstitial lung disease, non-infectious pneumonitis, or uncontrolled systemic diseases (e.g., diabetes mellitus, hypertension, pulmonary fibrosis, and acute pneumonitis).\n8. Any unresolved grade \\>=2 toxicity (according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0) resulting from previous treatment, except for anemia, alopecia, and skin hyperpigmentation.\n9. Prior treatment with anti-programmed death-1 (PD-1)\u002FPD-L1 antibody or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody.\n10. Pregnant or breastfeeding women.\n11. Known or tested positive for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).\n12. Known or suspected history of allergy to any of the relevant drugs used in the study.",{"count":381,"type":20},122,[90],"This prospective, randomized phase II trial is designed to evaluate whether low-dose short-course radiotherapy differs from common-dose short-course radiotherapy in terms of efficacy when both regimens are sequentially combined with CAPOX, a PD-1 monoclonal antibody, and interleukin-2 (IL-2) in patients with locally advanced rectal cancer. The study is based on findings from our previous single-center, single-arm PRIDE01 study, in which neoadjuvant short-course radiotherapy followed by systemic chemoimmunotherapy and IL-2 demonstrated encouraging antitumor activity relative to historical short-course radiotherapy-based approaches. The current trial aims to provide more robust clinical evidence regarding the potential role of low-dose radiotherapy combined with IL-2 as a sensitization strategy in multimodal neoadjuvant therapy. By comparing complete response rates between the two radiotherapy dose levels, this study may help define an optimized neoadjuvant approach and support future organ-preservation strategies for patients with locally advanced rectal cancer.",[43,385],"Radiotherapy",[187,189,188],"2026-06-09",{"date":260,"type":49},{"date":390,"type":49},"2026-05-20",{"date":392,"type":20},"2030-12-31",{"name":198,"class":56},{"id":395,"slug":4,"hasResults":11,"nctId":396,"briefTitle":397,"officialTitle":398,"acronym":399,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":401,"targetDuration":4,"studyType":21,"phases":403,"briefSummary":405,"conditions":406,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":409,"completionDateStruct":411,"leadSponsor":413,"locationsCount":416},"100531875","NCT06205485","Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer","A Phase 3 Randomized Trial Of Neoadjuvant Chemotherapy, Excision And Observation Versus Chemoradiotherapy For Early Rectal Cancer","NEO-RT","Inclusion Criteria:\n\n* Histologically confirmed invasive, well-moderately differentiated rectal adenocarcinoma, mismatch repair proficient.\n* MRI stage cT1 not eligible for transanal surgery or cT2-T3ab\\*. \\* T3a: \\\u003C1mm depth invasion, T3b: 1-5mm depth of invasion.\n* cN0 stage based on pelvic MRI - including absence of radiographic evidence of mesorectal nodal metastasis, tumour deposits or extramural venous invasion (EMVI).\n* M0 stage based on no evidence of metastatic disease by CT imaging of chest, abdomen and pelvis.\n* Mid to low-lying tumour eligible for transanal excision in the opinion of the treating surgeon.\n* Medically fit to undergo radical TME surgery as per treating surgeon's decision.\n* Participant is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaires in either English or French or Spanish.\n* Age of at least 18 years.\n* No contraindications to protocol chemotherapy.\n* Adequate normal organ and marrow function: ANC ≥ x 10\\^9\u002FL; platelet count ≥ 100 x 10\\^9\u002FL; bilirubin \\\u003C 1.5 UNL, excluding Gilbert's syndrome; Estimated creatinine clearance of ≥ 50ml\u002Fmin\n* Patient must have an ECOG performance of \\\u003C2 (or Karnofsty ≥ 60%).\n* Must be accessible for treatment and follow-up\n* Males and females of reproductive potential must have agreed to use a highly effective contraceptive method during and for 6 months after completion of chemotherapy.\n* HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.\n\nExclusion Criteria:\n\n* Pathologic high-risk factors on diagnostic biopsy: high histologic grade (poorly differentiated), mucinous or signet ring histology.\n* Patients with visible pelvic sidewall nodes on MRI.\n* Patients with unequivocal determination of nodal disease that, in the opinion of the investigator, would prohibit protocol therapy administration.\n* Previous pelvic radiation for any reason, including brachytherapy alone.\n* Patients who have had primary lesion excised prior to enrollment. If a patient has had partial excision prior to enrollment, there must be gross residual disease endoscopically for patient to be eligible.\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Prior treatment for rectal cancer.\n* Patients with known dihydropyrimidine dehydrogenase deficiency (DYPD).\n* Potential trial participants should have recovered from clinically significant adverse events of their most recent therapy\u002Fintervention prior to enrollment.\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.\n* Any contra-indications to undergo MRI imaging.\n* Presence of anterior lesions above or near peritoneal reflection rendering the patient ineligible for a transanal tumour excision.\n* T3 tumours invading or abutting the internal sphincter.",{"count":402,"type":20},250,[404],"PHASE3","This study is being done to answer the following questions: Is the chance of rectal cancer responding the same if chemotherapy alone is given before limited surgery compared to chemotherapy and radiation therapy given together before limited surgery? If radiation therapy is not given, is quality of life better?",[43],"2026-06-08",{"date":387,"type":49},{"date":410,"type":49},"2024-06-26",{"date":412,"type":20},"2030-06-30",{"name":414,"class":415},"Canadian Cancer Trials Group","NETWORK",109,{"id":418,"slug":4,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":115,"enrollmentInfo":423,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":425,"conditions":426,"keywords":427,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":430,"lastUpdatePostDateStruct":431,"startDateStruct":432,"completionDateStruct":433,"leadSponsor":435,"locationsCount":199},"100616498","NCT07306390","Distribution and Analysis of Metastatic Lymph Nodes in Colorectal Cancer Patients (DIAMOND)","DIAMOND","Inclusion Criteria:\n\n* Aged between 18 and 80 years\n* Pathologically confirmed adenocarcinoma of the colon or rectum\n* Underwent radical resection for colorectal cancer with a D3 lymphadenectomy and lymph nodes were submitted for pathological examination according to standardized station-based and distance-based protocol\n* No distant metastasis or distant metastasis within 6 months after surgery\n* No history of other malignant tumors or severe systemic diseases\n* No immune diseases or inflammatory bowel diseases\n* Non-emergency surgery\n* With complete clinicopathological and follow-up data\n\nExclusion Criteria:\n\n* Pathologically confirmed benign tumors or non-adenocarcinoma malignancies\n* Underwent local excision or palliative resection\n* Regional lymph nodes were not dissected or submitted for pathological examination according to the unified station-based or distance-based protocol\n* With distant metastasis or distant metastasis within 6 months after surgery\n* Dual or multiple primary colorectal cancers or concurrent other malignant tumors\n* Had a previous diagnosis of immune diseases or inflammatory bowel disease such as ulcerative colitis or Crohn's disease\n* Underwent emergency surgery\n* Had incomplete clinicopathological or follow-up data",{"count":424,"type":20},1200,"The goal of this observational study is to learn about the spatial distribution and significance of metastatic lymph nodes in colorectal cancer patients. The main question it aims to answer is:\n\n* What is the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer?\n* Can the spatial distribution pattern of metastatic lymph nodes in patients with colorectal cancer guide clinical practice? Participants should undergo regular follow-up examinations for at least 5 years after the surgery.",[31,43],[299,428,429],"Lymph Node Metastasis","Spatial Distribution","2026-06-07",{"date":387,"type":49},{"date":46,"type":20},{"date":434,"type":20},"2028-01-31",{"name":436,"class":56},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":438,"slug":4,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":444,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":446,"conditions":447,"keywords":451,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":199},"100628883","NCT07467434","FOLFIRINOX Induction Chemotherapy for Synchronous Liver Metastases","Multicenter Cohort Study of Mid\u002FLower Rectal Cancer With Resectable Synchronous Liver Metastases Treated With FOLFIRINOX Induction Chemotherapy","SYNCHRONOX","Inclusion Criteria:\n\n* Adult subjects aged 18 years and older\n* Adenocarcinoma of the middle and\u002For lower rectum pMMR T3, T4, and\u002For N+\n* Resectable synchronous liver metastases\n\nExclusion Criteria:\n\n* Minor under the age of 18.\n* Presence of extrahepatic metastases\n* Induction chemotherapy with FOLFIRINOX of less than 2 courses",{"count":445,"type":20},550,"SYNCHRONOX is a multicenter cohort (retrospective then prospective) intending to include 550 patients with mid or low rectal adenocarcinoma (pMMR, T3-T4 and\u002For N+) and resectable synchronous liver metastases, treated upfront with at least two cycles of induction FOLFIRINOX chemotherapy. The primary objective is to determine, at 18 months, the R0 resection rate of both tumor sites (rectum and liver), while secondary objectives focus on 3 year overall and progression free survival, radiological and pathological responses, postoperative morbidity and mortality, and comparison of the different surgical strategies after FOLFIRINOX.",[43,448,449,450],"Synchronous Liver Metastases","Antineoplastic Combined Chemotherapy Protocols","Surgical Therapy",[452,453],"Prospective observational multicentric cohort","Retrospective observational multicentric cohort","2026-06-05",{"date":387,"type":49},{"date":457,"type":49},"2026-05-01",{"date":459,"type":20},"2034-05-01",{"name":461,"class":56},"Assistance Publique - Hôpitaux de Paris",{"id":463,"slug":4,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":21,"phases":471,"briefSummary":472,"conditions":473,"keywords":474,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":477,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":7},"100607397","NCT07188025","ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer","Adjuvant Chemotherapy for Prevention of Recurrence in Patients With Detectable ctDNA After Surgery in High-Risk Rectal Cancer","REACT","Inclusion Criteria\n\n* Detectable ctDNA in the postoperative blood sample\n* Age ≥ 18 years\n* WHO performance score 0-1\n* Informed consent for PLCRC with specific consent for additional blood withdrawals and offering of future experimental research\n* Informed consent for the REACT trial.\n* Histological confirmed rectal cancer; either treated with neoadjuvant (chemo)radiotherapy, and\u002For clinical\u002Fpathological T3\u002FT4 and\u002For N+ in case no neoadjuvant therapy was administered.\n* Eligible to receive treatment with combination adjuvant chemotherapy (CAPOX\u002FFOLFOX) according to the treating physician.\n* Mentally competent and able to read and understand Dutch language.\n\nExclusion Criteria:\n\n* Metastatic disease\n* Another malignancy in previous 5 years, with the exception of treated carcinoma in situ or skin cancer other than melanoma\n* Incomplete primary tumour resection (R1 or R2 resection)\n* Contra-indication for fluoropyrimidines or oxaliplatin\n* Neoadjuvant oxaliplatin based systemic treatment, e.g. treated with the RAPIDO regimen consisting of short course radiotherapy followed by 6 cycles of CAPOX or 9 cycles of FOLFOX prior to surgery\n* Patients with a clinical complete response, who will not undergo surgery.\n* Pregnant and lactating women\n* History of psychiatric disability judged by the investigator to be clinically significant, precluding informed consent or interfering with compliance of the intervention group\n* Serious concomitant systemic disorders that would compromise the safety of the patient or his\u002Fher ability to complete the study, at the discretion of the investigator\n* Serious infections (uncontrolled or requiring treatment)\n* Current or recent (within 28 days prior to randomisation) treatment with another investigational drug or participation in another study interfering with the primary endpoint.",{"count":470,"type":20},103,[404],"The goal of this clinical trial is to investigate whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable ctDNA after surgery.\n\nThe main research question the REACT study aims to answer is:\n\n\\- Does adjuvant chemotherapy improve disease-free survival in patients with high-risk rectal cancer with detectable ctDNA after surgery?\n\nInterventions:\n\n\\- Patients with detectable ctDNA after surgery and randomised to the experimental group will be offered adjuvant chemotherapy (4 cycles CAPOX\u002F6 cycles FOLFOX) within 12 weeks after surgery.",[43],[475,476],"ctDNA","Adjuvant Chemotherapy",{"date":387,"type":49},{"date":479,"type":49},"2025-10-14",{"date":481,"type":20},"2035-10",{"name":483,"class":56},"Erasmus Medical Center",{"id":485,"slug":4,"hasResults":11,"nctId":486,"briefTitle":487,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":17,"enrollmentInfo":491,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":493,"conditions":494,"keywords":495,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":199},"100424289","NCT04804956","Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer","Mesorectal Microbiome and Metabolome as a Prognostic Factor in Patients With Rectal Cancer and Analysis of it's Applicability in Neoadjuvant Treatment","BIORECTUM","Inclusion Criteria:\n\n* Patients with colorectal cancer that will undergo elective surgery\n* Patients diagnosed with non-oncological disease with an indication for elective surgery.\n* Age ≥ 18 years\n* Histology proven adenocarcinoma or adenoma with or without chemotherapy or neoadjuvant radiochemotherapy\n* Tumoral stage equal or grater than T1\n* Attempt to R0 resection\n* Signed informed consent by the patient and by the researcher\n* Dietary Questionnaire completed\n\nExclusion Criteria:\n\n* Colorectal tumor with different histology to adenocarcinoma or adenoma\n* History of colorectal cancer surgery different to the local excision\n* Patients with psychiatric illness, addiction or disorder with inability to understand informed consent\n* Inability to read or understand any of the languages of the informed consent and questionnaires (Catalan, spanish)\n* Another synchronous malignancy\n* Emergency Surgery\n* Any patient that medical characteristics present an individual risk raised to be included and complete the study\n* Severe kidney or liver disease\n* Systemic disease with inflammatory activity, such as rheumatoid arthritis, Crohn's disease, asthma, chronic infection (HIV,TBC).\n* Pregnancy and lactation\n* Severe disorder of eating behaviour\n* Clinical symptoms and sings of infection in the previous month\n* Antibiotic, antifungal and antiviral treatment for the last 3 months\n* Anti-inflammatory chronic treatment\n* Major psychiatric antecedents\n* Excessive alcohol intake or drug abuse",{"count":492,"type":20},100,"The equilibrium of intestinal microorganisms is essential for health an imbalance has been associated with an increased risk in the development of different pathologies; including colorectal cancer.\n\nRectal cancer is the third most common neoplasm worldwide and the complete excision of the mesorectum is a major prognostic factor.\n\nThe identification of microorganisms in the adipose tissue that surrounds the small intestine in inflammatory diseases, together with bacterial alterations found in colonic mucosa and feces in patients with rectal cancer in comparison with healthy individuals indicates that microbiome alteration plays an essential role in pathogenesis.\n\nThe mesorectal microbiome in rectal cancer patients stills unknown and given its importance in the prognostic of the disease the goal of this study is to identify microbial profiles that allow predicting rectal cancer patients with a poor prognosis.",[43],[496,497,498,499,500],"Rectal Neoplasms","Colorectal surgery","Gastrointestinal Microbiome","Metabolomics","Microbiome",{"date":311,"type":49},{"date":503,"type":49},"2021-04-01",{"date":505,"type":20},"2028-04-01",{"name":507,"class":415},"University Hospital of Girona Dr. Josep Trueta",{"id":509,"slug":4,"hasResults":11,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":199},"100624022","NCT07404228","Multidimensional Study Designed to Develop a Methodological Framework Based on MRI Data to Predict Pathological Complete Response (pCR) in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Treatment","RESTAGE","Inclusion Criteria for the preclinical phase :\n\n* Age ≥18 years old;\n* Have a confirmed diagnosis of locally advanced rectal cancer;\n* Have completed neoadjuvant chemoradiotherapy;\n* Be a candidate for surgical treatment with total mesorectal excision;\n* Be willing and able to provide written informed consent;\n* Affiliation to the French Social Security System.\n\nInclusion criteria for the clinical phase:\n\n* Age ≥18 years old;\n* Have a confirmed diagnosis of locally advanced rectal cancer;\n* Require neoadjuvant chemoradiotherapy or have completed neoadjuvant chemoradiotherapy;\n* Requires either surgical treatment or a non-surgical strategy (\"Watch-and-Wait\") after neoadjuvant chemoradiotherapy;\n* Be willing and able to provide written informed consent;\n* Affiliation to the French Social Security System.",{"count":515,"type":20},115,"Rectal cancer presents a significant global health challenge. Despite improvements in clinical outcomes, significant disparities persist across Europe. These differences are explained not only by the heterogeneity of risk factors and screening strategies, but also by variations in diagnostic and therapeutic approaches, which are highly dependent on medical imaging.\n\nStandard treatment for locally advanced rectal cancer based on staging MRI is neoadjuvant treatment (NAT), for tumour downsizing and downstaging, followed by total mesorectal excision. In a significant proportion of cases, radical surgery leads to substantial long-term complications like sexual and urinary dysfunction, fecal incontinence, and impairment in daily activities. Given that up to 42% of patients show complete tumor regression at pathology (i.e. pathological complete response pCR), to avoid unnecessary radical surgery, non-operative management has become an attractive alternative when there are no signs of viable tumour after NAT (i.e. clinical complete response cCR). Such patients are candidates for Watch-and-Wait (W\\&W), an established active surveillance policy in specialized centers worldwide relying on clinical examination, endoscopy and MRI.\n\nOn the other hand, W\\&W carries a risk of local regrowth (persistence of microscopic residual disease despite apparent cCR). Even in expert hands, assessment of tumor response is not perfect and local regrowth based on current selection methods occurs in \\~30% of cases. Although deferred surgery is a successful treatment with no apparent negative impact on local disease control, an increased rate of distant metastases has been recently reported.\n\nTherefore, there is a critical unmet clinical need to detect complete responses after NAT and avoid unnecessary surgery with its associated morbidity and quality of life impairment risks, while also improving sensitivity for residual microscopic disease that will result in local regrowth and associated reduced disease-free survival.\n\nRectal cancer poses a burden not only on healthcare systems, but also on patient well-being. Patients frequently suffer from feelings of isolation and helplessness when faced with unpredicted disease-related situations, given the common difficulties to access high quality information and communicate with attending physicians. As such, there is a clear need to unburden healthcare facilities from unnecessary hospital visits, while improving patient outcomes, engagement, support and care.",[43,518,519],"Chemoradiotherapy","Mri","2026-06-02",{"date":522,"type":49},"2026-06-04",{"date":524,"type":20},"2026-08",{"date":526,"type":20},"2029-11",{"name":528,"class":56},"Institut du Cancer de Montpellier - Val d'Aurelle",{"id":530,"slug":4,"hasResults":11,"nctId":531,"briefTitle":532,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":21,"phases":536,"briefSummary":537,"conditions":538,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":544,"locationsCount":199},"100600491","NCT07098182","Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)","Clinical Study Evaluating the Contribution of Preserving the Superior Left Colic Artery to the Vascularization of the Descending Colon Prior to Colorectal Anastomosis During Left-Sided or Rectal Resections for Colorectal or Ovarian Cancer. (Revascularisation Colique)","Inclusion Criteria:\n\n* Male\u002F female aged over 18 years,\n* Histologically proven left colon or rectal adenocarcinoma OR ovarian carcinoma (with potential colorectal resection),\n* Scheduled surgery for left colic or rectal carcinoma\u002F\u002F Scheduled surgery for ovarian carcinoma with potential colorectal resection,\n* Surgical indication of colo-rectal resection validated in RCP and confirmed during the operative exploration (ovarian cancer,\n* WHO Status \\\u003C 3\n* Patient who has given informed, written and express consent,\n* Patient (s) affiliated to a French social security.\n\nExclusion Criteria:\n\n* Contraindication to indocyanine green: thyroid adenoma, hyperthyroidism, hypersensitivity or allergy to one of the components, severe renal failure (GFR \\\u003C30 ml\u002Fmin\u002F1.73m2),\n* Patient with a history of abdominal vascular surgery\n* Patient (e) not having left colic artery on vascular mapping of preoperative abdominal-pelvic scanners,\n* Patient whose regular follow-up is not possible for psychological, family, social or geographical reasons,\n* Patient (s) under guardianship, curatorship or safeguard of justice,\n* Pregnant and\u002For breastfeeding patient,",{"count":235,"type":20},[23],"Colorectal cancers and ovarian cancers are respectively the 2nd and 5th cause of cancer mortality in France.\n\nSurgical resection is a crucial step in the therapeutic management of colorectal cancers. For advanced ovarian cancers, the objective of cytoreductive surgery is to obtain complete macroscopic resection with no visible residual disease. One or more digestive resections are often required to achieve this goal of complete surgery (usually a modified posterior pelvic exenteration with colorectal resection).\n\nA ligation of the inferior mesenteric artery at its origin is classically performed in left colectomies and rectal resection for colorectal cancers. This allows the resection of the colorectal segment with a complete mesocolic lymphadenectomy until the origin of the inferior mesenteric artery and a good mobilization of the descending colon to allow its anastomosis to the underlying rectal stump. This ligation of the inferior mesenteric artery at its origin is also frequently performed in cases of modified posterior pelvic exenteration for ovarian cancer.\n\nRecently, several studies suggest that arterial ligation of the inferior mesenteric artery could be performed below the emergence of the left colic artery. Its preservation requiring a meticulous vascular dissection would allow a better vascularization of the descending colon and of the colorectal anastomosis without affecting the carcinologic quality of the resection and the number of resected lymph-nodes. Indeed, the most feared complication during colorectal anastomosis is the anastomotic leakage whose rates are on average 15% in rectal cancer with low anastomosis and 6% in ovarian cancers.\n\nVerifying the adequate vascularization of the descending colon before performing the colorectal anastomosis is a crucial step in reducing the risk of postoperative fistula. However, quantifying this vascularization is challenging, and several techniques can be used to assess it. The gold standard technique involves measuring arterial pressure using a catheter inserted into the marginal artery of the descending colon. Other non-invasive techniques also use Doppler studies to calculate pressure in the marginal artery or assess oxygen saturation using a sterile sensor.\n\nStudies have shown that the use of indocyanine green in colorectal surgery, particularly to evaluate perfusion before the creation of an anastomosis, significantly reduces the rate of anastomotic leakage. Indocyanine green is a fluorescent dye that, after intravenous injection, binds to plasma proteins and allows tissue perfusion to be visualized using a fluorescence system.\n\nThe objective of this project is to show that the preservation of the left colic artery is possible and allows a better vascularization of the descending colon before colorectal anastomosis.",[43,31,40],{"date":522,"type":49},{"date":541,"type":49},"2025-11-27",{"date":543,"type":20},"2026-10",{"name":528,"class":56},{"id":546,"slug":4,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":21,"phases":552,"briefSummary":553,"conditions":554,"keywords":556,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":568},"100565075","NCT06637462","A Study of Response to Standard Treatment Before Surgery in People With Rectal Cancer","DISCRN in Rectal Cancer: DISseCting Response to Neoadjuvant Therapy in Rectal Cancer","Inclusion Criteria:\n\n* 18 years of age or older on day of signing informed consent.\n* Have a histologically confirmed diagnosis of invasive adenocarcinoma of the rectum with no known mismatch repair deficiency or Her2 amplification.\n* Eligible for and plan to initiate standard-of-care therapy with any of the following regimens:\n\n  * Induction fluoropyrimidine (capecitabine \\[preferred\\] or 5-FU) based chemoradiation\n  * With plan for consolidative CAPEOX, FOLFOX, or FOLIRINOX\n* Woman with childbearing potential who are negative for pregnancy test (urine or blood) and who agree to use an effective contraceptive method. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. Reliable contraception should be used from the time of screening and must be continued throughout the duration of treatment as per standard of care.\n\nExclusion Criteria:\n\n* Patients with a prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Patients with prior external beam radiation therapy to the pelvis or brachytherapy seed implantation of the prostate.\n* Patients who are pregnant or breastfeeding.\n* Men or women not using effective contraception.\n* Patients with a contraindication to MR imaging.\n* Patients on blood thinners prohibiting endoluminal tumor biopsies.",{"count":65,"type":20},[23],"The purpose of the study is to learn more about how the body responds to standard treatment (chemoradiation and chemotherapy). The study will use the results of testing down on participants' blook, tissue, and scans to learn more about how people with rectal cancer respond to chemoradiation and chemotherapy treatment and if it is useful for predicting whether a person's cancer get better, gets worse, or stats the same after treatment.",[43,555],"Adenocarcinoma of the Rectum",[557,558,559,560],"rectal cancer","adenocarcinoma of the rectum","Memorial Sloan Kettering Cancer Center","24-238","2026-06-01",{"date":520,"type":49},{"date":564,"type":49},"2024-10-09",{"date":566,"type":20},"2027-10-09",{"name":559,"class":56},6,{"id":570,"slug":4,"hasResults":11,"nctId":571,"briefTitle":572,"officialTitle":573,"acronym":574,"eligibilityCriteria":575,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":576,"targetDuration":4,"studyType":21,"phases":577,"briefSummary":578,"conditions":579,"keywords":581,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":583,"lastUpdatePostDateStruct":584,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":199},"100640978","NCT07616297","Higher Radiation Dose to the Tumor May Help Avoid Surgery in Rectal Cancer Patients","REctal Organ Preservation With a BOost Approach Using CBCT-based Online Adaptive radioTherapy","REBOOT","Inclusion Criteria:\n\n* Age ≥18 years\n* Eastern cooperative oncology group (ECOG) performance status ≤2\n* Histologically confirmed rectal adenocarcinoma\n* Non-locally advanced rectal cancer, defined as (magnetic resonance imaging (MRI)-based) T1-3, N0\u002FN1 (≤3 positive mesorectal lymph nodes), MX\u002FM0\n* Indication for curative treatment with organ preservation\n* Discussed in the multidisciplinary tumor board (MTB)\n* Written informed consent\n\nExclusion Criteria:\n\n* Previous radiotherapy in the pelvic area\n* Other malignancies, except for adequately treated basal cell carcinoma (BCC), at time of inclusion or within 3 years prior to inclusion\n* Contra-indications for (chemo)radiotherapy or surgery\n* Presence of lateral lymph nodes, cN2 status, extramural vascular invasion (EMVI) or mesorectal fascia involvement as seen on MRI\n* Mucinous defined tumor on MRI\n* Prior local excision of the primary tumor\n* DPD (dihydropyrimidine dehydrogenase) deficiency\n* Unable to understand the requirements of the study and to give written informed consent, as determined by the treating physician",{"count":7,"type":20},[23],"The goal of this prospective study is to evaluate if a higher radiation dose to the tumor can increase the organ preservation rate in non-locally advanced rectal cancer.",[43,580],"Radiation Oncology",[580,303,582],"Organ Preservation","2026-05-29",{"date":561,"type":49},{"date":586,"type":49},"2026-01-27",{"date":588,"type":20},"2030-08-01",{"name":590,"class":56},"Claudia Schuurhuizen",{"id":592,"slug":4,"hasResults":11,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":596,"eligibilityCriteria":597,"healthyVolunteers":11,"sex":16,"minAge":598,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":601,"conditions":602,"keywords":607,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":613,"leadSponsor":615,"locationsCount":199},"100619169","NCT07341126","Use of a Novel Camera to Check the Bowel After Polyp or Tumour Removal","Surveillance Digital Rectoscopy After Local Excision of Rectal Tumours","R-ALERT","Inclusion Criteria:\n\nAll participants who are capable of giving informed consent. All participants aged 16 years or over. All patients must have had a rectal tumour\u002F polyp removed within easy reach of the rigid sigmoidoscope.\n\nAll participants must be resident in the United Kingdom.\n\nExclusion Criteria:\n\nUnable to give informed consent. Under the age of 16 years","16 Years",{"count":600,"type":20},30,"1.1 Polyps or tumours in the lower part of the bowel (rectum) can be removed using instruments inserted through the bottom which avoids major surgery and the possibility of a stoma bag (colostomy). Afterwards, it is important to check the area with regular camera tests. If checks are delayed, re-growths could be serious and may be untreatable. COVID and other factors have led to long waiting lists for camera checks and in NHS Lothian around 20% of all camera checks are done more than 6 months late.\n\nThe investigators want to try a new camera and approach that would allow us to reduce waiting lists. Using a short camera called a 'rectoscope' to check the lower bowel has already been shown to be safe, comfortable and acceptable to patients with other conditions. In fact, patients are unlikely to feel or realise any difference between the rectoscope and standard camera tests.\n\nThe investigators want to show that this 'rectoscope' can be safely used in the outpatient clinic with an enema (suppository) instead of strong bowel medicine taken by mouth the day before. This would mean the camera checks happen on time and would reduce waiting lists for other important tests.\n\nThe investigators will include 30 patients across three stages of our study. In the first set of patients, the investigators will use the rectoscope alongside the usual endoscope in the endoscopy room using the usual oral bowel medicine. This stage will check the rectoscope is acceptable to the patient and the doctor. In the next 10 patients the investigators will use a suppository instead of oral bowel medicine still using both cameras. Finally, the investigators will use the rectoscope in the outpatient clinic with an suppository to show this is an easy, effective and acceptable way to deliver timely camera checks.",[603,604,43,605,606],"Bowel Cancer","Polyp Rectal","Rectal Adenocarcinoma","Rectal Adenoma",[608,609],"LumenEye","Rectoscopy","2026-05-28",{"date":583,"type":49},{"date":46,"type":20},{"date":614,"type":20},"2027-05-01",{"name":616,"class":56},"University of Edinburgh",{"id":618,"slug":4,"hasResults":11,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":4,"eligibilityCriteria":622,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":623,"enrollmentInfo":624,"targetDuration":4,"studyType":21,"phases":626,"briefSummary":627,"conditions":628,"keywords":630,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":634,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":199},"100300428","NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","A Phase I\u002FII Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","* INCLUSION CRITERIA:\n* Measurable (per RECIST V1.1 criteria, metastatic, or unresectable malignancy expressing G12V mutated KRAS as assessed by one of the following methods: RT-PCR on tumor tissue, tumor DNA sequencing, or any other CLIA-certified laboratory test on resected tissue. Patients shown to have tumors expressing G12V mutated NRAS and HRAS will also be eligible as these oncogenes share complete amino acid homology with G12V mutated KRAS for their first 80 N-terminal amino acids, completely encompassing the target epitope.\n* Patients must be HLA-A\\*11:01 positive as confirmed by the NIH Department of Transfusion Medicine.\n* Confirmation of the diagnosis of cancer by the NCI Laboratory of Pathology.\n* Patients must have:\n\n  * previously received standard systemic therapy for their advanced cancer and have been either non-responders or have recurred, specifically:\n\n    * Patients with metastatic colorectal cancer must have had at least two systemic chemotherapy regimens that include 5FU, leucovorin, bevacizumab, oxaliplatin, and irinotecan (or similar agents), or have contraindications to receiving those medications.\n    * Patients with pancreatic cancer must have received gemcitabine, 5FU, and oxaliplatin (or similar agents), or have contraindications to receiving those medications.\n    * Patients with non-small cell lung cancer (NSCLC) must have had appropriate targeted therapy as indicated by abnormalities in ALK, EGFR, or expression of PDL- 1. Other patients must have had platinum-based chemotherapy.\n    * Patients with ovarian cancer or prostate cancer must have had approved first-line chemotherapy.\n\nOR\n\n* declined standard treatment\n* Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and asymptomatic are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible. Patients\n\nwith surgically resected brain metastases are eligible.\n\n* Age greater than or equal to 18 years and less than or equal to 72 years.\n* Clinical performance status of ECOG 0 or 1\n* Patients must be willing to practice birth control from the time of enrollment on this study and 12 months after the last dose of combined chemotherapy for women and for 4 months after treatment for men.\n* Women of child-bearing potential must be willing to undergo pregnancy testing prior to the start of treatment because of the potentially dangerous effects of the treatment on the fetus.\n\nNOTE: Certain malignancies may secrete hormones that produce false positive pregnancy tests. Serial blood testing (e.g. HCG measurements) and\u002F or ultrasound may be performed for clarification.\n\n* Serology\n\n  * Seronegative for HIV antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive may have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n  * Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.\n* Hematology\n\n  * ANC greater than 1000\u002Fmm\\^3 without the support of filgrastim\n  * WBC greater than or equal to 2500\u002Fmm\\^3\n  * Platelet count greater than or equal to 80,000\u002Fmm\\^3\n  * Hemoglobin \\> 8.0 g\u002FdL. Subjects may be transfused to reach this cut-off.\n* Chemistry\n\n  * Serum ALT\u002FAST less than or equal to 5.0 times ULN\n  * Total bilirubin less than or equal to 2.0 mg\u002FdL, except in patients with Gilbert s Syndrome, who must have a total bilirubin less than 3.0 mg\u002FdL.\n* Patients must have either an eGFR \\> 60 mL\u002Fm (based on serum creatinine and lab nomogram) or a formal 6-24h CrCl \\> 60 mL\u002Fm.\n* Patients must have completed any prior systemic therapy at the time of enrollment.\n\nNote: Patients may have undergone minor surgical procedures or limited field radiotherapy within the four weeks prior to enrollment, as long as related major organ toxicities have recovered to less than or equal to grade 1.\n\n* Ability of subject to understand and the willingness to sign a written informed consent document.\n* Willing to sign a durable power of attorney.\n* Subjects must be co-enrolled on protocol 03C0277.\n\nEXCLUSION CRITERIA:\n\n* Large volume pulmonary irradiation.\n* Women of child-bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant.\n* Concurrent systemic steroid therapy.\n* Active systemic infections requiring anti-infective treatment, coagulation disorders, or any other active or uncompensated major medical illnesses.\n* Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease).\n* Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities.)\n* History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin.\n* History of coronary revascularization or ischemic symptoms\n* For select patients with a clinical history prompting cardiac evaluation: last known LVEF less than or equal to 45%.\n* For select patients with a clinical history prompting pulmonary evaluation: known FEV1 less than or equal to 50% or DLCO less than 60%.\n* Patients who are receiving any other investigational agents.","72 Years",{"count":625,"type":20},110,[331,90],"Background:\n\nA new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person. This therapy is called gene transfer using anti-KRAS G12V mTCR cells.\n\nObjective:\n\nTo see if anti-KRAS G12 V mTCR cells are safe and can shrink tumors.\n\nEligibility:\n\nAdults at least 18 years old with cancer that has the KRAS G12V molecule on the surface of tumors.\n\nDesign:\n\nIn another protocol, participants will:\n\nBe screened\n\nHave cells harvested and grown\n\nHave leukapheresis\n\nIn this protocol, participants will have the procedures below.\n\nParticipants will be admitted to the hospital.\n\nOver 5 days, participants will get 2 chemotherapy medicines as an infusion via catheter in the upper chest.\n\nA few days later, participants will get the anti-KRAS G12V mTCR cells via catheter.\n\nFor up to 3 days, participants will get a drug to make the cells active.\n\nA day after getting the cells, participants will get a drug to increase their white blood cell count. This will be a shot or injection under the skin.\n\nParticipants will recover in the hospital for 1-2 weeks. They will have lab and blood tests.\n\nParticipants will take an antibiotic for at least 6 months.\n\nParticipants will have visits every few months for 2 years, and then as determined by their doctor.\n\nVisits will be 1-2 days. They will include lab tests, imaging studies, and physical exam. Some visits may include leukapheresis or blood drawn.\n\nParticipants will have blood collected over several years.",[41,35,629,31,43],"Gastrointestinal Cancer",[631,632,633,358,187],"KRAS","HRAS","NRAS",{"date":583,"type":49},{"date":636,"type":49},"2017-09-21",{"date":638,"type":20},"2028-06-29",{"name":640,"class":641},"National Cancer Institute (NCI)","NIH",{"id":643,"slug":4,"hasResults":11,"nctId":644,"briefTitle":645,"officialTitle":646,"acronym":647,"eligibilityCriteria":648,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":649,"targetDuration":4,"studyType":21,"phases":651,"briefSummary":652,"conditions":653,"keywords":654,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":658,"lastUpdatePostDateStruct":659,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":80},"100637698","NCT07622017","KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer","Phase II Clinical Trial of KORTUC (KRC-01) Combined With Radiotherapy for Locally Advanced Rectal Cancer: Towards a New Organ Preservation Approach","K-BOOST","Inclusion Criteria:\n\n1. Males and females ≥ 18 years of age.\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n3. Histopathologically confirmed locally advanced rectal adenocarcinoma, stage III (high risk)\n4. No evidence of metastatic disease on computed tomography (chest and abdomen), including resectable metastases. (M0, and no oligometastases)\n5. At least one of the following criteria: cT4a, cT4b, presence of extramural invasion (EMVI+), cN2, involvement of the mesorectal fascia (MFI+), involvement of lateral lymph nodes (lat LN+)\n6. Adenocarcinoma located with a lower border less than 15 cm from the anal margin\n7. Primary resection without chemoradiotherapy is unlikely to achieve clear margins.\n8. Tumor lesion must be mesurable by endoscopic visual assessment\n9. Target tumor is accessible for intratumoral injections.\n10. Intention to undergo treatment including 5 Fu based chemoradiotherapy and CAPOX (6 cycles) or FOLFOX (9 cycles)\n11. Life expectancy \\> 6 months\n12. Acceptable organ functions, as evidenced by the following laboratory data:\n\n    1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.0×upper limit of normal (ULN).\n    2. Total serum bilirubin ≤ 1.5×ULN.\n    3. Absolute neutrophil count (ANC): ≥ 1500 cells\u002Fmm³.\n    4. Platelet count: ≥ 100,000 cells\u002Fmm³.\n    5. Hemoglobin: ≥ 9.0 g\u002FdL.\n    6. Serum creatinine levels ≤ 1.5×ULN, or calculated (by Cockcroft-Gault formula or other accepted formula) and measured creatinine clearance ≥50 mL\u002Fmin.\n    7. Amylase and lipase ≤ 1.5xULN.\n    8. Adequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ≤ 1.5.\n13. Women of childbearing potential must have a negative serum β-HCG pregnancy test within 7 days prior to the administration of the first study treatment and\u002For urine pregnancy 12 hours prior to the administration of the first study treatment.\n\n    1. Female subjects of childbearing potential should be willing to use a highly effective method of contraception or be surgically sterile or abstain from heterosexual activity during the study treatment and for at least 15 months after the last dose of oxaliplatin and 6 months after the last dose of capecitabine or 5-fluorouracil, whichever period is longer.. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for \\> 1 year. cf. section 7.8 \"Pregnancy and contraception\") Note: A woman is considered of childbearing potential following menarche and until becoming post-menopausal (≥ 12 months of non-therapy-induced amenorrhea) unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral oophorectomy, and bilateral salpingectomy. A \"highly effective\" birth control method is one which can achieve a failure rate of less than 1% per year when used consistently and correctly. Such methods include: combined (estrogen and progestogen containing) hormonal contraception; progestogen-only hormonal contraception associated with inhibition of ovulation; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomized partner (on the understanding that this is the only partner during the whole study duration), and sexual abstinence during the entire period of risk associated with study treatment. To prevent the risk of interaction between the study drug and hormonal contraceptives, hormonal contraceptives should be supplemented with a barrier method (preferably male condom). Following methods are considered as unacceptable methods (non-exhaustive list): periodic abstinence (calendar, symptothermal, post-ovulation methods) and withdrawal (coitus interruptus).\n    2. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy until at least 12 months after the last dose of oxaliplatin and 3 months after the last dose of capecitabine or 5-fluorouracil, whichever period is longer.\n\n    Also, it is recommended that women of childbearing potential partner use a highly effective method of contraception.\n14. Patients who either do not consent to a tumor biopsy or do not have accessible lesions will not be eligible.\n15. Patients should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed.\n16. Patient should be able and willing to comply with study visits and procedures as per protocol.\n17. Patient must be affiliated to a social security system or beneficiary of the same.\n\nExclusion Criteria:\n\n1. Patients not deemed fit for radiotherapy or preexisting condition which would deter radiotherapy, e.g., fistulas, severe ulcerative colitis (including subjects currently taking sulphasalazine), active Crohn's disease, prior adhesions.\n2. Patients with hypokalemia below the lower limit of normal, hypomagnesemia, hypocalcemia, or QT\u002FQTc interval \\>450 msec in males or \\>470 msec in females at inclusion are not eligible.\n3. Any Previous radiotherapy in the pelvic region.\n4. Contraindications to MRI (e.g., subjects with pacemakers, claustrophobia, excessive weight, etc.).\n5. Participation in another clinical study with an investigational product during the last 3 months.\n6. Prior rectal surgery.\n7. Prior investigational treatment for rectal cancer.\n8. Patients with known high microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) tumors are not eligible, as these patients may benefit from standard-of-care immunotherapy.\n9. High medical risk because of systemic diseases (e.g., uncontrolled infections, uncontrolled diabetes) in addition to the qualifying disease under study. Patients must not have any uncontrolled concurrent illness including, but not limited to, severe active or uncontrolled infection, symptomatic congestive heart failure, unstable, angina pectoris, cardiac arrhythmia, uncontrolled diabetes mellitus or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n10. Patients receiving therapeutic anticoagulation are not eligible. Prophylactic anticoagulation at low dose (e.g., thromboprophylaxis) may be allowed at the investigator's discretion, provided that the bleeding risk is considered minimal.\n11. Patients receiving concomitant treatment with brivudine or who have received brivudine within the previous 4 weeks.\n12. Peripheral sensory neuropathy grade ≥2 (for the future administration of oxaliplatin)\n13. Dihydropyrimidine deshydrogenase (DPD) deficiency. DPD status must be assessed prior to inclusion, and uracilemia testing is mandatory before initiation of fluorouracil-based treatment. Patients with unknown DPD status are not eligible.\n14. Concomitant medications\u002Fcomorbidities that may prevent the patient from receiving study treatments,\n15. Contraindication to fluoropyrimidines or oxaliplatin and capecitabin as mentioned in the SMPC of investigational medicinal products: FOLFOX is contraindicated in patients with known hypersensitivity to 5-fluorouracil, oxaliplatin, leucovorin, or other platinum compounds; in those with severe renal impairment (CrCl \\\u003C30 mL\u002Fmin), significant bone marrow suppression, uncontrolled infections, or pre-existing grade ≥2 peripheral neuropathy. It is also contraindicated in individuals with complete or partial dihydropyrimidine dehydrogenase (DPD) deficiency due to the risk of severe 5-FU toxicity, as well as in cases of severe hepatic dysfunction, pregnancy, and breastfeeding. Caution is advised in patients with poor performance status (ECOG ≥3).\n16. Yellow fever vaccine and live attenuated vaccines are contraindicated due to the risk of severe vaccine-induced infection. Note: The currently authorized COVID-19 vaccines are not live vaccines and therefore can be safely administered.\n17. Known history of human immunodeficiency virus (HIV) infection or seropositive results consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV) infection.\n18. Pregnant or breastfeeding women or intending to become pregnant during the clinical investigation.\n19. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent.",{"count":650,"type":20},24,[90],"This phase II clinical trial is evaluating whether adding KRC-01 injections to standard chemoradiotherapy may improve treatment outcomes in patients with locally advanced rectal cancer without metastases.\n\nKRC-01 is an investigational product designed to improve the effectiveness of radiotherapy by increasing oxygen levels inside tumors, which may help radiation work better. KRC-01 contains hydrogen peroxide and sodium hyaluronate and is injected directly into the tumor before radiotherapy sessions.\n\nPrevious clinical experience in Japan, including studies in several types of cancer, suggested that this approach may improve tumor oxygenation and enhance the effect of radiotherapy.\n\nThe main objective of the K-BOOST study is to evaluate how many patients achieve a complete clinical response after treatment with chemoradiotherapy combined with intratumoral KRC-01 injections, potentially allowing some patients to avoid surgery. Surgery may still be recommended depending on the individual response to treatment.\n\nApproximately 24 patients will participate in this multicenter French study. The experimental treatment period lasts approximately 26 weeks, and participants will be followed for up to 2 years.",[43],[655,656,657,582],"Intratumoral","chemoradiotherapy","advanced rectal cancer","2026-05-27",{"date":520,"type":49},{"date":661,"type":20},"2026-07",{"date":663,"type":20},"2030-07",{"name":665,"class":56},"Gustave Roussy, Cancer Campus, Grand Paris",{"id":667,"slug":4,"hasResults":11,"nctId":668,"briefTitle":669,"officialTitle":670,"acronym":671,"eligibilityCriteria":672,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":233,"enrollmentInfo":673,"targetDuration":4,"studyType":21,"phases":675,"briefSummary":676,"conditions":677,"keywords":679,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":689,"lastUpdatePostDateStruct":690,"startDateStruct":692,"completionDateStruct":694,"leadSponsor":695,"locationsCount":226},"100637489","NCT07605611","Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Rectal Cancer Undergoing Ultra-Low Anterior Resection","A Multicenter, Randomized Clinical Study of Somatostatin Plus Clear Liquid Diet Versus Diverting Stoma in Patients With Low and Mid Rectal Cancer Undergoing Ultra-Low Anterior Resection","SC-Stoma","Inclusion Criteria:\n\n1. Adults aged 18 to 75 years\n2. Patients with stage I to III rectal malignancy who are scheduled to undergo low anterior resection at a participating gastrointestinal surgery center\n3. The lower edge of the tumor is 8 cm or less from the dentate line, or 10 cm or less from the anal verge, based on preoperative colonoscopy, imaging, or digital rectal examination\n4. The planned anastomosis is expected to be 2 cm or less from the dentate line, or 4 cm or less from the anal verge\n5. Patients have two or more risk factors for anastomotic leakage as assessed by the study team\n6. American Society of Anesthesiologists physical status classification is grade 3 or lower\n7. Body mass index is less than 30 kg\u002Fm²\n8. The patient, or the patient's legally authorized representative, is willing and able to provide written informed consent\n\nExclusion Criteria:\n\n1. Has another colorectal malignant tumor at the same time\n2. The final anastomosis after surgery is more than 2 cm from the dentate line, or more than 4 cm from the anal verge\n3. Has metastatic disease before surgery\n4. Is pregnant\n5. Has a mental illness or addictive disorder that would prevent participation in the clinical trial\n6. Requires emergency surgery\n7. Has inflammatory bowel disease\n8. Is allergic to somatostatin or is unable to tolerate somatostatin\n9. For participants assigned to the no-stoma group, the surgeon decides that a stoma is required\n10. Has received neoadjuvant drug therapy less than 2 weeks before surgery, or radiotherapy less than 8 weeks before surgery\n11. Has any other condition that makes it impossible to follow the study protocol",{"count":674,"type":20},72,[23],"The goal of this clinical trial is to learn if somatostatin plus a clear liquid diet can help prevent severe leakage after rectal cancer surgery in adults with low or mid rectal cancer who are scheduled to have ultra-low anterior resection. These patients have a higher risk of leakage where the bowel is joined together after surgery.\n\nThe main questions it aims to answer are:\n\nDoes somatostatin plus a clear liquid diet prevent severe leakage within 1 month after surgery about as well as a prophylactic diverting stoma?\n\nWhat medical problems, bowel function problems, recovery outcomes, and quality of life outcomes do participants have after surgery and during follow-up?\n\nResearchers will compare somatostatin plus a clear liquid diet without a diverting stoma to prophylactic diverting stoma to see if the somatostatin plus clear liquid diet regimen can provide similar protection against severe leakage while reducing the need for stoma creation.\n\nParticipants will:\n\nHave rectal cancer surgery with the bowel joined very close to the anus\n\nBe randomly assigned to receive either somatostatin plus a clear liquid diet for 7 days after surgery without a diverting stoma, or a prophylactic diverting stoma\n\nHave follow-up assessments of leakage, postoperative complications, bowel function, recovery quality, and quality of life\n\nComplete follow-up visits or assessments for up to 3 years after surgery",[43,678],"Anastomotic Leakage",[303,680,681,682,683,684,685,686,687,688],"Ultra-low anterior resection","Anastomotic leakage","Severe anastomotic leakage","Diverting stoma","Prophylactic stoma","Somatostatin","Clear liquid diet","Bowel function","Quality of life","2026-05-22",{"date":691,"type":49},"2026-05-26",{"date":693,"type":49},"2025-11-17",{"date":412,"type":20},{"name":696,"class":56},"Tongji Hospital",""]